At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09606 DUALITYBIO-B
Market Closed 05-22 16:08:22
222.800
-1.600
-0.71%
High228.000
Low219.400
Vol364.96K
Open220.000
D1 Closing224.400
Amplitude3.83%
Mkt Cap20.15B
Tradable Cap20.15B
Total Shares90.43M
T/O81.38M
T/O Rate0.40%
Tradable Shares90.43M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Duality Biotherapeutics Launches $40 Million Stock Buyback; Shares Rise 3%
China International Capital Corporation: National Policy Optimizes Initial Pricing Mechanism for Innovative Drugs, Pharmaceutical Sector Set for High-Quality Development
Duality Biotherapeutics Inc is an investment holding company principally engaged in clinical-stage biopharmaceuticals. The Company is dedicated to the development of antibody-drug conjugate (ADC) innovative therapeutics to treat cancer and autoimmune diseases. The Company's primary drug product candidates include DB-1303/BNT323, DB-1311/BNT324, DB-1310, DB-1305/BNT325, DB-1419 and DB-2304. The Company's products are mainly used for the targeted treatment of endometrial cancer (EC), breast cancer (BC), small-cell lung cancer (SCLC), castration-resistant prostate cancer (CRPC), esophageal squamous cell carcinoma (ESCC), as well as head and neck squamous cell carcinoma (HNSCC). The Company principally conducts its businesses in domestic and overseas markets.